HTH-01-091 (TFA)

• UNSPSC Description:

  HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research[1].

• Target Antigen:

  CDK; DYRK; GSK-3; MELK; mTOR; Pim; RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;JAK/STAT Signaling;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hth-01-091-tfa.html

• Purity:

  99.48

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1N([C@H]2CC[C@H](CN(C)C)CC2)C3=C(CN1)C=NC4=CC=C(C5=CC(Cl)=C(O)C(Cl)=C5)C=C34.OC(C(F)(F)F)=O

• Molecular Weight:

  613.46

• References & Citations:

  [1]Huang HT, et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 Sep 19;6:e26693.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported